



# Rabies Work Group Update

Sharon Frey, MD, FACP, FIDSA

Chair, ACIP Rabies Work Group

**ACIP Meeting**

**February 24, 2021**

# Work Group Members

## ACIP Members

*Sharon Frey (chair)*

*Lynn Bahta*

## Liaison Representatives

*AAFP- James Stevermer*

*NASPHV- Katie Brown and Sally Slavinski*

*NACCHO- Matt Zahn*

*AAP- Elizabeth Bennett*

*APhA- Karl Hess*

*NACI- Julie Emili and Linlu Zhao*

*FDA- Paula Agger and Robin Levis*

*NIH- Eun-Chung Park*

## Invited Consultants

*Subject Matter Expert- Deborah Briggs*

*Subject Matter Expert- Susan Moore*

*Travel medicine- David Shlim*

*Emergency Medicine – Greg Moran*

*APHL-Michael Pentella*

## CDC

*Rabies Work Group leads – Agam Rao*

*& Jesse Blanton*

*Immunization Safety Office – Pedro Moro*

*Division of Global Migration and*

*Quarantine- Kristina Angelo*

# ACIP rabies sessions until now: PreP

- **October 2018:** Introduced formation of WG
- **October 2019 and February 2020**
  - Reviewed vaccine safety, and work group considerations for changes to PrEP
  - Gathered feedback from committee about data they would need to make changes to 2008 ACIP recommendations
  - Conveyed WG conclusions about pediatric patients having similar responses (if not more robust) than those of healthy persons
  - Showed evidence to support WG move to use data from intradermal series to influence intramuscular series recommendations
  - Explained why 0.5 IU/mL should be the minimum rabies antibody titer cut-off
  - Redefined risk categories for PrEP
  - Presented GRADE and EtR for 2 PrEP policy questions


# WG activities since last ACIP meeting

- **Understanding pre-exposure prophylaxis (PrEP) costs, including those incurred by PrEP recipients**
- **Post-exposure prophylaxis (PEP)**
  - Developing guidance for front line clinicians who make decisions about whether PEP is indicated
  - Evaluating two Rabies Immune Globulin (RIG) products licensed since 2008 ACIP recommendations
  - Assessing data about the current ACIP recommendation for RIG infiltration around a wound and for remainder administered intramuscularly
  - Evaluating immunogenicity of PEP in persons aged  $\geq 65$

# WG's goal for today

- PrEP
  - Address questions raised by the ACIP about PrEP costs
  - Summarize clinical guidance presented at previous meetings
  - Recap policy questions, Evidence tables, and Evidence to Recommend frameworks
  - Commence vote on two proposed policy questions
- PEP
  - Provide background information about PEP
  - Convey WG conclusions about RIG

# Anticipated timeline



# Today's agenda

- Rabies pre-exposure prophylaxis: Summary of background information important to today's vote
- Rabies pre-exposure prophylaxis: Summary of GRADE and EtR

-----

- Rabies post-exposure prophylaxis: Background
- Work group interpretations of data about rabies immune globulin
- Next steps

===== Break and public comment

- PrEP vote (two recommendations)

*All presentations are provided by Dr. Agam Rao (CDC/NCEZID)*

# Thank you!

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

